Fox Business - The Power to Prosper
Search Site

John Lechleiter

Eli Lilly CEO: 2015 is a key transition year for us

Eli Lilly CEO John Lechleiter discusses new products, 2015 outlook, its Alzheimer’s disease program and animal health division.

Read More

  1. Eli Lilly Warns of '14 Revenue Headwinds

    Eli Lilly (NYSE:LLY) warned it may miss its 2014 revenue target due to foreign-exchange and emerging market headwinds, but the drug maker also unveiled a $5 billion ...

  2. Eli Lilly CEO Returns to Post After Heart Surgery

    Eli Lilly's (NYSE:LLY) longtime CEO John Lechleiter returned to his post as chief executive on Monday after a nearly two-month medical leave as he recovered from sch...

  3. Lilly CEO to undergo surgery, CFO Rice to become interim CEO

    Eli Lilly & Co's longtime Chief Executive John Lechleiter will undergo surgery next Monday for a dilated aorta, but is expected to make a full recovery from the pote...

  4. Lilly CEO Lechleiter to undergo surgery for dilated aorta

    Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to w...

  5. Lilly's 4Q Profit Falls on Generic Competition

    Eli Lilly (NYSE:LLY) revealed a 4% decline in fourth-quarter profit due to ongoing effects of the so-called "patent cliff," but still topped Wall Street expectations...

  6. Eli Lilly Forecasts Stronger 2013

    Eli Lilly (NYSE:LLY) reaffirmed its in-line fiscal 2012 guidance on Friday and unveiled an upbeat outlook for the following year.The company also said it continues t...

  7. Eli Lilly to Expand Insulin-Manufacturing Facilities

    Eli Lilly & Co. (LLY) plans to expand its Indianapolis insulin-manufacturing facilities in a multimillion-dollar investment to meet growing demand in the U.S.This ma...

  8. Eli Lilly Alzheimer's Drug Fails in Late-Stage Trial

    Eli Lilly (NYSE:LLY) said on Friday that its experimental treatment for Alzheimer's disease failed to meet two late-stage studies' primary goals, however the drug gi...

  9. Lilly's Alzheimer Shows Promise; Misses Goals

    Eli Lilly & Co. (LLY) said solanezumab, a highly anticipated potential treatment for Alzheimer's disease, failed to reach its set goals in either of two Phase 3 stud...

  10. Bristol-Myers, Lilly Remain Optimistic Despite Patent Woes

    Two major U.S. drug companies took big hits to quarterly profits and sales because patent expirations for their top products cleared the way for generic competition....

  11. Bristol-Myers, Lilly 2Q Sales Drop Amid Patent Expirations

    Bristol-Myers Squibb (NYSE:BMY) and Eli Lilly (NYSE:LLY) both reported weaker quarterly earnings and sales on Wednesday as they struggled to stem losses from patent ...

  12. Eli Lilly 2nd-Quarter Net Falls 23% as Zyprexa Sales Drop; Raises Year View

    Eli Lilly & Co. (LLY) said its second-quarter profit declined 23%, as the drug maker continues to feel the effects of the recent patent expiration for antipsychotic ...

  1. Eli Lilly CEO: We hope to resume growth next year

    Eli Lilly CEO John Lechleiter discusses his outlook for growth and when he expects to have patent expirations behind.

  2. Lilly CEO sees margins hitting pre-patent cliff levels by ‘19

    Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.

  3. Eli Lilly CEO on cancer: We’re in store for further advances

    Eli Lilly CEO John Lechleiter on where we are in the fight for cancer.

  4. Eli Lilly CEO talks pipeline growth

    Eli Lilly CEO John Lechleiter gives his outlook for growth and new products.

  5. Eli Lilly CEO talks M&A

    Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.

  6. Eli Lilly Projects In-Line '14 Profit Slump

    Mirroring forecasts from analysts, Eli Lilly (NYSE:LLY) projected a steep drop in 2014 revenue and earnings on Tuesday as the drug giant continues to grapple with th...

  7. The 'Accidental CEO': Eli Lilly's John Lechleiter

    When he began his career as a senior organic chemist in 1979, John Lechleiter had a passion for science -- chemistry was his first love -- and a desire to work in th...

‹ Prev123Next ›
Freebase CC-BY
Source: John Lechleiter on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL